For example, Na/H+ exchanger inhibition with Amiloride, lysosomal activity by V‐ATPase inhibitors or lysosomotropic agents, or macromolecular conjugates (e.g., Abraxane) targeting macropinocytosis could in principle provide non‐targeted therapies for a wide spectrum of Wnt‐driving cancer mutations – such as APC, Axin, RNF43, ZNRF‐3, R‐Spondin 2 or 3 translocations, and activating β‐catenin point mutations. Here, AXIN1 is linked to cancer.